Skip to main content

Natus Medical Board of Directors Strengthens Governance and Focuses on Growth

Written by Customer Service on . Posted in Public Companies.

  • Establishes Environmental, Social & Governance Committee
  • Transitions Quality & Compliance Committee to Innovation & Quality Committee
  • Names Thomas J. Sullivan Senior Independent Director

PLEASANTON, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) — Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company’s Board of Directors established an Environmental, Social, and Governance (ESG) committee and transitioned the role of the Quality & Compliance Committee to the Innovation & Quality committee on September 30th, 2021.

The Innovation & Quality committee will provide oversight of the Company’s focus on accelerating growth through product and process innovation and quality. Natus’ success with investments in research and development to advance patient care, coupled with compliance with quality systems and regulatory requirements related to product safety and efficacy are critical to the achievement of the Company’s strategic growth objectives. Dr. Bryant Moore will chair the Innovation & Quality committee.

The ESG committee will enable the Board to ensure ESG risks and opportunities are integrated into the Company’s strategy; provide oversight of the Company’s on-going commitment to sustainability, human capital development, health & safety, data security, diversity & inclusion, and other ESG pillars; and champion transparency in ESG reporting for shareholders. Alice Schroeder will chair the ESG committee.

“My fellow Board members and I are excited that these two committees heighten the Board’s focus on ESG, Innovation and Quality. These are cornerstones of growth and our efforts to create long-term shareholder value. We look forward to collaborating with Jonathan and the Natus Management Team to continue many existing best practices and implement opportunities to improve at all levels of the Company,” said Joshua Levine, Chairman of the Board. Mr. Levine added, “I would also like to thank Tom Sullivan for assuming the additional responsibilities as Senior Independent Director. With his board and management experience, he is a valuable resource and sounding board for myself and our Directors.”

“The foundation of our business and products centers on improving patients’ lives, which is core to our social responsibility and sustainability. Innovating and improving the quality of our products enables Natus to make an impact and contribute to society. We have made noteworthy progress in our ESG initiatives in recent years and recognize that further progress in this area is a journey. We look forward to working with our Board to increase the transparency of our accomplishments and to broaden our sustainability in the future,” said Jonathan Kennedy, President and Chief Executive Officer of Natus.

About Natus Medical Incorporated

Natus Medical Incorporated improves patient outcomes using the most comprehensive product solutions, depth of training and continuing customer care when diagnosing and treating central nervous and sensory system disorders for patients of all ages.

Additional information about Natus Medical Incorporated can be found at https://natus.com.

Contacts:
Natus Medical Incorporated
Drew Davies
Executive Vice President and Chief Financial Officer
(925) 223-6700
InvestorRelations@Natus.com  

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.